See more : TG Venture Acquisition Corp. (TGVC) Income Statement Analysis – Financial Results
Complete financial analysis of 180 Life Sciences Corp. (ATNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 180 Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Response Oncology, Inc. (ROIX) Income Statement Analysis – Financial Results
- China Northern Rare Earth (Group) High-Tech Co.,Ltd (600111.SS) Income Statement Analysis – Financial Results
- TIE Kinetix N.V. (TIE.AS) Income Statement Analysis – Financial Results
- Akanda Corp. (AKAN) Income Statement Analysis – Financial Results
- Indorama Ventures Public Company Limited (I93.F) Income Statement Analysis – Financial Results
180 Life Sciences Corp. (ATNF)
About 180 Life Sciences Corp.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 0.00 | 0.00 |
| Gross Profit | -105.68K | -109.00K | -116.30K | -125.33K | -72.24K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.78M | 2.43M | 3.95M | 2.29M | 2.04M | 1.07M | 0.00 |
| General & Administrative | 10.69M | 15.47M | 11.69M | 3.32M | 5.89M | 7.67M | 343.88K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 38.83K | 12.96M | 0.00 | 0.00 |
| SG&A | 10.69M | 15.47M | 11.69M | 3.36M | 18.85M | 7.67M | 343.88K |
| Other Expenses | 0.00 | 246.34B | 770.60K | 264.74K | 250.40K | 0.00 | 0.00 |
| Operating Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Cost & Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Interest Income | 0.00 | 26.67K | 186.21K | 1.09M | 181.41K | 12.24K | 663.02K |
| Interest Expense | 44.83 | 26.67K | 186.21K | 1.09M | 185.14K | 0.00 | 0.00 |
| Depreciation & Amortization | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 23.08K | 52.52K |
| EBITDA | -22.13M | -17.79M | -20.05M | -5.52M | -20.79M | -8.72M | -343.88K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.48M | -17.90M | -15.64M | -5.65M | -20.86M | -8.74M | -343.88K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.81M | -21.77M | -4.71M | -5.26M | -4.54M | -5.75M | 663.02K |
| Income Before Tax | -22.28M | -39.67M | -20.35M | -10.90M | -25.40M | -14.50M | 319.13K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.35M | 942.75K | 23.20K | 20.43K | 9.50K | -1.00 | 195.37K |
| Net Income | -19.94M | -38.73M | -20.32M | -12.01M | -25.39M | -14.50M | 123.76K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -52.60 | -387.26 | -247.86 | -255.46 | -875.66 | -1.45K | 12.38 |
| EPS Diluted | -52.59 | -387.18 | -246.32 | -251.32 | -874.45 | -1.45K | 12.38 |
| Weighted Avg Shares Out | 379.00K | 100.00K | 82.00K | 47.00K | 29.00K | 10.00K | 10.00K |
| Weighted Avg Shares Out (Dil) | 379.09K | 100.02K | 82.51K | 47.77K | 29.04K | 10.00K | 10.00K |
7 Reddit Penny Stocks to Buy for a Biotech Boom
180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021
ATNF Stock: Over 30% Increase Intraday Explanation
What's Happening With ATNF Stock And CELC Stock?
5 Reddit Penny Stocks Seeing the Most Chatter Friday
DISCB and 6 Other Reddit Stocks Waiting for a Short Squeeze
180 Life Sciences Continues Uptrend With Cannabinoid And Anti-Inflammatory Research
180 Life Science Rallies 18%: Technical Levels To Watch
ATNF Stock: Why 180 Life Sciences Is Soaring Higher Today
ATNF Stock Price Increased Over 50% Pre-Market: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports